First AD

Second AD

Expert Insights on the LAURA Trial: Osimertinib After CRT in Unresectable Stage III EGFRm NSCLC as a New Standard of Care

Video content above is prompted by the following:

Please provide some background on the LAURA trial evaluating osimertinib after definitive CRT in unresectable stage III 

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer 

OncLive Insights

The discussion focuses on the LAURA trial, which demonstrated that osimertinib significantly improved progression-free survival in patients with EGFR-mutated (EGFRm) locally advanced non–small cell lung cancer (NSCLC) after chemoradiotherapy (CRT), establishing it as a new standard of care with manageable safety concerns.